David J. Endicott is the CEO of Alcon and leads the Alcon Executive Leadership Team. He joined Alcon in July of 2016 as President, Commercial & Innovation, and Chief Operating Officer. Prior to Alcon, Mr. Endicott was President of Hospira Infusion Systems, a Pfizer company. During his tenure there, he led Hospira’s medical device business through a turnaround, carve-out, and eventual sale. Critical to the turnaround, he advanced the company’s product pipeline, returned its products to market from quality disruptions, and accelerated global growth. Before joining Hospira, Mr. Endicott served as an officer and executive committee member of Allergan where he spent more than 25 years of his career in leadership roles across Europe, Asia, Latin America, as well as the US. He accelerated Allergan’s international growth and successfully built new markets focused on medical specialties in the areas of ophthalmology, plastic surgery, dermatology and aesthetic medicine. Mr. Endicott holds an undergraduate degree in Chemistry from Whitman College, an MBA from the University of Southern California, and is a graduate of the Advanced Management Program at the Harvard Business School. He has also served on the Board of Directors of AdvaMed, Zeltiq (ZLTQ), and Orexigen (OREX).